文献速递血液透析通路

维持性血透患者血管通路相关超额死亡的量化研究

Quantifying vascular access-associated excess mortality in maintenance hemodialysis patients.
PubMed 文献 · J Vasc Surg · 2026-04-22

该回顾性队列研究纳入2016至2019年北美大型透析机构146967例新发血透患者,采用逆概率治疗加权和时间依赖生存分析评估血管通路类型与生存的关系。导管起始中位生存1106天,动静脉通路1290天;加权后动静脉通路起始死亡风险低25%,持续使用低62%,但超额风险至少部分反映基线健康差异而非直接因果。

要点

  • 导管起始血透患者中位生存较动静脉通路短184天,持续导管使用差异达778天。
  • 加权后动静脉通路起始死亡风险低25%,持续使用低62%。
  • 感染相关死亡组间差异小,超额风险部分源于患者选择和基线健康差异。

核心结论

  • 导管使用与较动静脉通路更高的死亡风险相关。
  • 动静脉通路使用在各分析中均与更好生存相关,但观察性数据无法确定确切获益幅度。
  • 超额风险至少部分反映基线健康和患者选择差异而非直接因果效应。

研究设计与样本

  • 回顾性队列研究,纳入2016至2019年北美大型透析机构146967例新发血透患者。
  • 采用逆概率治疗加权和时间依赖生存分析等多种分析策略。

主要发现

  • 导管起始患者中位生存1106天,动静脉通路起始1290天,差异184天,限制性平均生存时间比88%。
  • 持续导管使用中位生存448天,持续动静脉通路1226天,限制性平均生存时间差778天,比52%。
  • 加权后动静脉通路起始死亡风险低25%(HR 0.75,95%CI 0.73-0.76),持续使用低62%(HR 0.38,95%CI 0.36-0.40)。
  • 感染相关死亡组间差异小,各比较组中占死亡的8.6%-10.6%。

临床怎么用

  • 应优先考虑动静脉通路作为血透起始和维持通路以改善生存。
  • 解读导管相关死亡风险时需考虑患者基线健康差异和选择偏倚。

局限性

  • 观察性设计无法确定因果效应,确切获益幅度不能确定。
  • 超额风险至少部分反映基线健康和患者选择差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Central venous catheters (CVCs) are commonly linked with higher mortality in hemodialysis (HD) patients compared with arteriovenous accesses (AVAs). However, patients with CVCs often have greater comorbidities, complicating causal interpretation. This study aimed to assess the association between vascular access type and survival adjusting for relevant confounders. METHODS: In this retrospective cohort study, data from 146,967 incident HD patients treated between 2016 and 2019 at a large North American dialysis organization (Fresenius Medical Care North America) were analyzed. Multiple analytic strategies were conducted including inverse probability treatment weighted and time-dependent survival analyses. RESULTS: Among 146,967 incident HD patients, median survival was 1106 days for those initiating with a CVC compared with 1290 days for patients with an AVA, corresponding to a 184-day difference and an 88% restricted mean survival time (RMST) ratio. In the sustained access analysis, median survival was 448 days for CVC-only vs 1226 days for AVA-only patients (RMST difference = 778 days, RMST ratio = 52%). After inverse probability treatment weighting, AVA initiation was associated with a 25% lower mortality risk (hazard ratio: 0.75, 95% confidence interval: 0.73-0.76) and sustained AVA use with a 62% lower risk (hazard ratio: 0.38, 95% confidence interval: 0.36-0.40). Differences in infection-related deaths between the groups were small (8.6%-10.6% of deaths in all comparison groups). CONCLUSIONS: CVC use was associated with higher mortality compared with AVA. Although AVA use remained linked with better survival across analyses, the precise magnitude of any access-related benefit cannot be determined within the constraints of observational data. There are strong indications that the excess risk at least partially reflects differences in baseline health and patient selection rather than a direct causal effect.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hofmann AG, Leinweber ME, Lama S, et al. Quantifying vascular access-associated excess mortality in maintenance hemodialysis patients. J Vasc Surg. 2026. PMID: 42031148. doi:10.1016/j.jvs.2026.03.790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。